Covid-19 roundup: In­dia moves for­ward with re­view of Pfiz­er and As­traZeneca vac­cine can­di­dates; Chi­na's Sino­vac gets $515M to dou­ble vac­cine pro­duc­tion

Less than a week af­ter Pfiz­er and BioN­Tech land­ed a his­toric au­tho­riza­tion for their Covid-19 vac­cine in the UK, In­dia is speed­ing up its own re­view of the can­di­date and an­oth­er from As­traZeneca, an un­named source told Reuters. 

As­traZeneca sub­mit­ted its ap­pli­ca­tion for emer­gency use ap­proval in In­dia on Mon­day, Reuters re­port­ed, while Pfiz­er filed over the week­end. Mass sup­ply will be han­dled by the Serum In­sti­tute of In­dia, the world’s largest vac­cine pro­duc­er by vol­ume.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.